RARE

Ultragenyx Pharmaceutical Inc.

RARE · CIK 1515673 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$673M
20182025
Net Income−$575M
20182025
Operating CF−$466M
20182025
Free Cash Flow−$472M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.7B$0.6B$0.4B$0.4B$0.4B$0.1B$0.0B$0.0B
Cost of Revenue———————$0.0B
Gross Profit————————
R&D Expense$0.8B$0.7B$0.6B$0.7B$0.5B$0.4B$0.4B$0.3B
SG&A Expense$0.3B$0.3B$0.3B$0.3B$0.2B$0.2B$0.2B$0.1B
Operating Income$-0.5B$-0.5B$-0.6B$-0.6B$-0.4B$-0.3B$-0.4B$-0.4B
Net Income$-0.6B$-0.6B$-0.6B$-0.7B$-0.5B$-0.0B$-0.1B$-0.1B
EPS (Basic)$-5.83$-6.29$-8.25$-10.12—$-0.37$-1.73$-1.73
EPS (Diluted)$-5.83$-6.29$-8.25$-10.12—$-0.37$-1.73$-1.73

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$1.5B$1.5B$1.5B$1.5B$1.5B$1.8B$1.1B$0.7B
Current Assets$1.0B$0.8B$0.7B$0.9B$0.9B$1.3B$0.9B$0.5B
Cash & Equivalents$0.4B$0.2B$0.2B$0.1B$0.3B$0.7B$0.4B$0.1B
Total Liabilities$1.6B$1.2B$1.2B$1.2B$0.6B$0.6B$0.5B$0.1B
Current Liabilities$0.4B$0.3B$0.3B$0.3B$0.2B$0.2B$0.1B$0.1B
Stockholders' Equity$-0.1B$0.3B$0.3B$0.4B$0.9B$1.2B$0.7B$0.6B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.5B$-0.4B$-0.5B$-0.4B$-0.3B$-0.1B$-0.3B$-0.3B
Investing Cash Flow$0.2B$-0.0B$0.2B$-0.3B$-0.2B$-0.2B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.1B$0.1B$0.0B$0.0B$0.0B
Financing Cash Flow$0.5B$0.4B$0.4B$0.5B$0.1B$0.6B$0.7B$0.3B
← Companies